| Course | HCR 563 Fundamentals of Regulatory Affairs |
|---|---|
| Module | Module 5 |
| Paper type | Annotated bibliography |
| Length | About 547 words, 4 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 563 Module 5
Annotated Bibliography: Decentralized Clinical Trials and Their Regulation
Student Name
MS in Regulatory Science, Arizona State University
HCR 563: Fundamentals of Regulatory Affairs
Instructor Name
Month Day, Year
Annotated Bibliography: Decentralized Clinical Trials and Their Regulation
Introduction
Decentralized clinical trials (DCTs) use telemedicine, home visits, local laboratories, direct-to-participant drug shipment and digital tools to reduce the need for participants to travel to research sites. Their use expanded quickly during the COVID-19 pandemic, and regulators have since issued guidance on how to run them safely. This bibliography gathers five sources that explain what DCTs are, what the evidence shows and how regulators view them.
Annotations
1. FDA Guidance on Decentralized Elements
Summary: FDA's final guidance explains how sponsors can use decentralized elements, such as telehealth visits, local health care providers and direct shipment of investigational products, and sets expectations for investigator oversight, delegation, safety monitoring and data collection (U.S. Food and Drug Administration, 2024). Evaluation: As agency guidance it is nonbinding but authoritative, and it reflects the FDA's current thinking. Relevance: It is the starting point for any U.S. sponsor designing a DCT, because it identifies what the agency will look for at inspection.
2. A Systematic Review of Decentralized Methods
Summary: Searching eight databases and screening more than 18,000 records, the reviewers included 45 randomized trials in a quantitative analysis and 117 documents in a qualitative analysis (Rogers et al., 2022). Trials were too varied to combine statistically, so the review could not show whether decentralized methods improve recruitment, retention or cost; qualitative themes centered on value, burden, safety and equity. Evaluation: A rigorous search with an honest conclusion that the evidence is immature. Relevance: It cautions against claims that DCTs are proven to improve enrollment.
3. European Regulators' Perspective
Summary: Interviews with 20 European regulators found that they saw opportunities in reduced participant burden, broader access for underserved patients and data closer to real-world use, along with concerns about investigator oversight and participant safety when physical examinations are limited; hybrid designs were favored (de Jong et al., 2022). Evaluation: A small qualitative study, but rare direct evidence of regulators' views. Relevance: It shows that European acceptance is likely to favor hybrid rather than fully remote trials.
4. Stakeholder Views on Recruitment and Retention
Summary: Forty-eight stakeholders, including trial managers, investigators, nurses, vendors and patient representatives, described trust, perceived burden and personal values as drivers of joining and staying in DCTs, and saw greater need for communication to build trust without in-person contact (Coyle et al., 2022). Evaluation: Rich qualitative data from a range of roles, though participants themselves were represented mainly through patient advocates. Relevance: It suggests that consent and retention plans in DCTs need deliberate contact schedules.
5. The Future of Decentralized Trials
Summary: This review describes the components of DCTs, their potential to reduce cost and burden and widen participation and the regulatory, technological and data integrity challenges that remain (Van Norman, 2021). Evaluation: A readable overview from a journal focused on translational science, written early in the model's expansion. Relevance: It frames the questions regulators and sponsors still face.
Synthesis
The sources agree that decentralized trials can lower participant burden and may widen access, but they also agree that evidence of better recruitment and retention is limited and that investigator oversight and safety are the main regulatory concerns. Hybrid designs, combining site visits with remote elements, appear to be the most acceptable path for regulators on both sides of the Atlantic.
References
Coyle, J., Rogers, A., Copland, R., De Paoli, G., MacDonald, T. M., Mackenzie, I. S., & Trials@Home Consortium. (2022). A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs). Trials, 23(1), 614. https://doi.org/10.1186/s13063-022-06521-4
de Jong, A. J., van Rijssel, T. I., Zuidgeest, M. G. P., van Thiel, G. J. M. W., Askin, S., Fons-MartÃnez, J., De Smedt, T., de Boer, A., Santa-Ana-Tellez, Y., Gardarsdottir, H., & Trials@Home Consortium. (2022). Opportunities and challenges for decentralized clinical trials: European regulators' perspective. Clinical Pharmacology & Therapeutics, 112(2), 344-352. https://doi.org/10.1002/cpt.2628
Rogers, A., De Paoli, G., Subbarayan, S., Copland, R., Harwood, K., Coyle, J., Mitchell, L., MacDonald, T. M., Mackenzie, I. S., & Trials@Home Consortium. (2022). A systematic review of methods used to conduct decentralised clinical trials. British Journal of Clinical Pharmacology, 88(6), 2843-2862. https://doi.org/10.1111/bcp.15205
U.S. Food and Drug Administration. (2024). Conducting clinical trials with decentralized elements [Guidance for industry]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements
Van Norman, G. A. (2021). Decentralized clinical trials: The future of medical product development? JACC: Basic to Translational Science, 6(4), 384-387. https://doi.org/10.1016/j.jacbts.2021.01.011
What the HCR 563 Module 5 instructions ask for
Assignment 3 in HCR 563, due in Week 5, is an annotated bibliography on a relevant topic in clinical research, regulations or regulatory affairs, or food science. The topic is your choice, so pick one narrow enough that five to eight sources can cover it well and current enough that regulators have said something about it, such as decentralized trials, real-world evidence, artificial intelligence in devices, multi-cancer early detection tests or food allergen labeling. Each annotation should summarize the source, evaluate its strength and explain its relevance to regulatory work. A mix of source types, government guidance, systematic reviews and primary studies, shows you understand the range of evidence a regulatory question draws on. Format entries in APA style and follow any annotation length your instructor posts. The bibliography is one of four assignments sharing 400 points.
How this HCR 563 Module 5 example is built
A short introduction defines decentralized trials and explains why regulators care about them. Five annotations follow, each with a short descriptive heading and three labeled parts: summary, evaluation and relevance, with in-text citations and key numbers from the source. The sources are deliberately varied: an FDA guidance, a systematic review, a qualitative study of regulators, a qualitative study of stakeholders and a review article. A synthesis paragraph states what the sources agree on and where the evidence is thin. Full APA references appear in the reference list. Each annotation reports its source's key numbers, and the five together cover guidance, review, regulator views, stakeholder views and future direction, so the reader sees the topic from several sides.
HCR 563 Module 5 rubric: what earns full marks
The bibliography shares HCR 563's 400 assignment points with the other three assignments. Credit goes to a focused, relevant topic, credible and varied sources, accurate summaries, honest evaluations of each source's strength, a clear statement of each source's relevance to regulation and correct APA formatting. News stories and vendor brochures cost marks, as do annotations that stop at summary, sprawling topics and misquoted figures. Readers value a closing synthesis because it shows the student can see the state of evidence across sources, a skill regulatory affairs work depends on. Varied source types, guidance as well as studies, often separate strong bibliographies from adequate ones.
HCR 563 Module 5 help with common mistakes
Narrow your topic until five to eight sources can cover it. Include at least one regulator's guidance and one systematic review if available. For each source, write three labeled parts. Record sample sizes and key numbers as you read. State how the source matters to a regulator or sponsor. End with a short synthesis. If your topic has little regulatory literature, the desk can help you find guidance documents or switch topics. Consortium names and long author lists trip up APA formatting, so compare each entry with the published article. Keep each annotation to roughly the same length so none dominates. Read your synthesis aloud to confirm it says something no single source says.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 563 and MS in Regulatory Science sample papers
- HCR 563 Module 3: Assignment 1: Global Device Registration Slides (Japan)
- HCR 563 Module 4: Assignment 2: Building Quality Into Clinical Trials
- HCR 544 Module 7: Food Safety Individual Project Paper
- HCR 555 Module 6: Assignment 5: A Pharmacogenomic Risk-Minimization Plan
- HCR 579 Module 2: Written Assignment 1: Evaluating a Translational Study
- HCR 576 Module 1: Paper: Product Profile for a Drug Under Development
HCR 563 Module 5 questions, answered
Where can I find a free HCR 563 Module 5 sample paper?
The page above carries the complete Assignment 3 annotated bibliography on decentralized clinical trials.
What topics fit the HCR 563 annotated bibliography?
Any relevant topic in clinical research, regulations or regulatory affairs, or food science, narrow enough for five to eight sources.
What is a decentralized clinical trial?
A trial in which some or all activities, such as visits, testing or drug delivery, happen at or near participants' homes instead of research sites.
Do decentralized trials improve recruitment?
The evidence is still limited; a 2022 systematic review could not confirm which methods improve recruitment, retention or cost.
What should each annotation include?
The source's main point, its reliability and its use to someone working in regulatory affairs.